Spectroscopic study of self-assembly of anti-hepatitis C virus sofosbuvir drug with bio-polymeric nanoparticles for improving the drug release effect

Self-assembly of Sofosbuvir drug (SOF) anti-hepatitis C virus (HCV) with bio-polymeric nanoparticles such as chitosan nanoparticles (Cs NPs) and polyvinyl alcohol nanoparticles (PVA NPs), the novel composites have been characterized successfully by different analysis such as Energy-dispersive X-ray spectroscopy (EDX), Scanning electron microscopy (SEM), UV-Visible spectrophotometer (UV-Vis) and Fourier Transmittance Infrared (FT-IR). The improvement of the Sofosbuvir effect as a result of loading drug on the bio-polymer NPs surface has been detected by the UV-Vis, and fluorescence spectroscopy techniques. The improvement of SOF efficiency was revealed via studying the drug release of SOF from biopolymers NPs surface at pH 7.4, UV-Vis spectra used for the releasing process. The binding constant (K-b) value was reported at 0.000055 and 0.3613 min(-1) for Cs and PVA NPs respectively. Also, the value of K-SV was documented at 0.0014 and 7.16 min(-1) for Cs@SOF and PVA@SOF hybrid nanocomposite. The incorporation rate (k) of SOF on the surface of biopolymer nano molecules was calculated to be 0.00812 and 0.0165 min(-1) for Cs and PVA NPs, respectively. Besides the observed value of (n) was close to the unit 0.74 and 0.86 for Cs and PVA NPs, respectively. The SOF released from Cs NPs surface was documented at 0.09 mg after 24 h, while PVA NPs reported at 0.7 mg at the same time and the release efficiency is 56.5 and 73% for Cs@SOF and PVP@SOF, respectively. From the results, we suggest Cs/SOF and PVA/SOF hybrid nanocomposites have spectroscopic results that make them promising candidate drugs, but need to the clinical trials. (C) 2021 Elsevier B.V. All rights reserved.

Automated summary

The self-assembly of Sofosbuvir drug with bio-polymeric nanoparticles has been characterized successfully by various analysis methods, showing promising potential as candidate drugs that require clinical trials for validation.